Certest Pharma is excited to announce a strategic partnership with Emervax, a leader in RNA vaccine development. This collaboration combines Certest Pharma’s advanced ionizable lipids and LNP formulation expertise with Emervax’s cutting-edge RNA vaccine technologies.

According to this collaboration, Certest will provide its high-performing ionizable lipids and thermostable lipid nanoparticles, designed to ensure greater stability for RNA-based vaccines, while Emervax will contribute its innovative approach to RNA therapeutics. This partnership will focus on creating next-generation RNA vaccines that are not only more stable but also optimized for targeted delivery, ensuring broader reach and more effective immunizations.

Nelson Fernandes, CEO of Certest Pharma, said,

“Joining forces with Emervax marks an important step in our mission to transform RNA vaccine delivery. Together, we will enhance vaccine stability and targeting, making a meaningful impact on healthcare worldwide.”

Peter Weinstein, Co-Founder and CEO of Emervax, added,

“We are excited to partner with Certest Pharma to leverage their expertise in drug delivery. This collaboration has the potential to significantly improve global access to RNA vaccines and drive forward innovations in the field.”

This partnership underscores Certest Pharma’s ongoing commitment to advancing RNA-based therapeutics and revolutionizing vaccine delivery.